Name: Targeting of Drugs 3: The Challenge of Peptides and Proteins (en Inglés)
Price: 54790.00 CLP
Availability: InStock
Author: Gregoriadis, Gregory ; Florence, Alexander T. ; Poste, George
ISBN: 9781461362760

portada Targeting of Drugs 3: The Challenge of Peptides and Proteins (en Inglés)

Targeting of Drugs 3: The Challenge of Peptides and Proteins (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Gregoriadis, Gregory ; Florence, Alexander T. ; Poste, George

Idioma

Inglés

N° páginas

129

Encuadernación

Tapa Blanda

ISBN13

9781461362760

Categorías

Farmacología
Bioquímica
Jardinería

Targeting of Drugs 3: The Challenge of Peptides and Proteins (en Inglés)

Gregoriadis, Gregory ; Florence, Alexander T. ; Poste, George (Autor) · Springer · Tapa Blanda

Libro Nuevo Importado

Envío: 16 a 21 días háb.

$ 109.570$ 54.790

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 54.790

Llega entre el 04 Ago y el 11 Ago a Santiago, Región Metropolitana. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Targeting of Drugs 3: The Challenge of Peptides and Proteins (en Inglés)"

'nle NATO Advanced studies Institute series "Targeting of Drugs" was originated in 1981. It is now a major international forum, held every two years in cape Sounion, Greece, in which the present and the future of this important area of research in drug delivery is discussed in great depth. Five previous ASIs of the series dealt with drug carriers of natural and synthetic origin, their interaction with the biological milieu, with ways by which the latter influences such interaction and strategies by which milieu interference curtailing the ftmction of drug carriers is circumvented or relieved. 'nle present book contains the proceedings of the 6th NATO ASI "Targeting of Drugs: 'nle nias who, as chairperson of the Local Corrmittee, contriruted to the success of the Institute. 'nle ASI was held under the sponsorship of NATO Scientific Affairs Division and co-sponsored and generously financed by SmithKline Beecham Phannaceuticals (King of Prussia). Financial assistance was also provided by Syntex Laboratories Inc. (Palo Alto), Syntex Research (Palo Alto) and pfizer Central Research (Sandwich).